skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of trastuzumab in the management of HER2-positive metastatic breast cancer

Review

(2480) Views  (842) Full article downloads

Authors: Andrea Milani, Filippo Montemurro, Luisa Gioeni, et al

Published Date November 2010 Volume 2010:2 Pages 93 - 109
DOI: http://dx.doi.org/10.2147/BCTT.S6070

Andrea Milani1,2, Filippo Montemurro1, Luisa Gioeni1, Massimo Aglietta1,2, Giorgio Valabrega1,2
1Oncological Department, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy; 2University of Turin Medical School, Department of Biomedical Sciences and Human Oncology, Turin, Italy

Abstract: Breast cancer is a major health issue in developed countries. Overexpression of HER2, a member of epidermal growth factor receptor family, occurs in 20%–30% of breast cancers. HER2 drives the cancer cells to develop a more aggressive phenotype, to metastasize to viscera and central nervous system, and to be less sensitive to chemotherapeutic agents. Trastuzumab (Herceptin®) is a monoclonal antibody directed against the extracellular domain of HER2. As single agent or with chemotherapy, trastuzumab improves survival of HER2-positive breast cancers. In the past years, trastuzumab has completely revolutionized the scenario of the treatment of HER2-positive breast cancer, representing one of the most remarkable examples of targeted therapy in oncology. However, issues such as the best chemotherapeutic companion to associate with trastuzumab, cardiac toxicities, and clinical resistance still require tremendous efforts by researchers. Here, we review pharmacology, efficacy studies, and toxicities of trastuzumab in metastatic breast cancer. Moreover, we provide some insights on resistance to therapy. Finally, we briefly discuss trastuzumab’s place in the clinical setting.

Keywords: HER2, trastuzumab, breast cancer, cardiotoxicity, resistance






Readers of this article also read:

New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review
Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
Lapatinib: new opportunities for management of breast cancer
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University